Cerebrospinal fluid distribution and pharmacokinetics of ponatinib in Ph1 + acute lymphoblastic leukemia

2.

Tang

J

,

Yu

J

,

Cai

J

, et al.

Prognostic factors for CNS control in children with acute lymphoblastic leukemia treated without cranial irradiation

.

Blood

.

2021

;

138

(

4

):

331

-

343

.

3.

Surapaneni

UR

,

Cortes

JE

,

Thomas

D

, et al.

Central nervous system relapse in adults with acute lymphoblastic leukemia

.

Cancer

.

2002

;

94

(

3

):

773

-

779

.

4.

Pinnix

CC

,

Yahalom

J

,

Specht

L

,

Dabaja

BS

.

Radiation in central nervous system leukemia: guidelines from the International Lymphoma Radiation Oncology Group

.

Int J Radiat Oncol Biol Phys

.

2018

;

102

(

1

):

53

-

58

.

5.

Gökbuget

N

,

Boissel

N

,

Chiaretti

S

, et al.

Management of ALL in adults: 2023 ELN recommendations from a European expert panel

.

Blood

.

2024

;

143

(

19

):

1903

-

1930

.

6.

Tanguy-Schmidt

A

,

Rousselot

P

,

Chalandon

Y

, et al.

Long-term follow-up of the imatinib GRAAPH-2003 study in newly diagnosed patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: a GRAALL study

.

Biol Blood Marrow Transplant

.

2013

;

19

(

1

):

150

-

155

.

7.

Ravandi

F

.

How I treat Philadelphia chromosome–positive acute lymphoblastic leukemia

.

Blood

.

2019

;

133

(

2

):

130

-

136

.

8.

Rousselot

P

,

Coudé

MM

,

Gokbuget

N

, et al.

Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL

.

Blood

.

2016

;

128

(

6

):

774

-

782

.

9.

Foà

R

,

Vitale

A

,

Vignetti

M

, et al.

Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

.

Blood

.

2011

;

118

(

25

):

6521

-

6528

.

10.

Jabbour

E

,

Short

NJ

,

Jain

N

, et al.

Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial

.

Lancet Haematol

.

2023

;

10

(

1

):

e24

-

e34

.

11.

Alfayez

M

,

Kantarjian

HM

,

Short

NJ

, et al.

Safety and efficacy of blinatumomab in patients with central nervous system (CNS) disease: a single institution experience [abstract]

.

Blood

.

2018

;

132

(

suppl 1

):

2702

.

12.

Slayton

WB

,

Schultz

KR

,

Kairalla

JA

, et al.

Dasatinib plus intensive chemotherapy in children, adolescents, and young adults with Philadelphia chromosome–positive acute lymphoblastic leukemia: results of Children’s Oncology Group trial AALL0622

.

J Clin Orthod

.

2018

;

36

(

22

):

2306

-

2314

.

13.

Pfeifer

H

,

Wassmann

B

,

Hofmann

W-K

, et al.

Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome-positive acute leukemias treated with imatinib mesylate

.

Clin Cancer Res

.

2003

;

9

(

13

):

4674

-

4681

.

14.

Wolff

NC

,

Richardson

JA

,

Egorin

M

,

Ilaria

RL

.

The CNS is a sanctuary for leukemic cells in mice receiving imatinib mesylate for Bcr/Abl-induced leukemia

.

Blood

.

2003

;

101

(

12

):

5010

-

5013

.

15.

Porkka

K

,

Koskenvesa

P

,

Lundán

T

, et al.

Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia

.

Blood

.

2008

;

112

(

4

):

1005

-

1012

.

16.

Shen

S

,

Chen

X

,

Cai

J

, et al.

Effect of dasatinib vs imatinib in the treatment of pediatric Philadelphia chromosome–positive acute lymphoblastic leukemia: a randomized clinical trial

.

JAMA Oncol

.

2020

;

6

(

3

):

358

-

366

.

17.

Cortes

JE

,

Kim

D-W

,

Pinilla-Ibarz

J

, et al.

A phase 2 trial of ponatinib in Philadelphia chromosome–positive leukemias

.

N Engl J Med

.

2013

;

369

(

19

):

1783

-

1796

.

18.

Jabbour

E

,

Short

NJ

,

Ravandi

F

, et al.

Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study

.

Lancet Haematol

.

2018

;

5

(

12

):

e618

-

e627

.

19.

Ravi

K

,

Franson

A

,

Homan

MJ

, et al.

Comparative pharmacokinetic analysis of the blood-brain barrier penetration of dasatinib and ponatinib in mice

.

Leuk Lymphoma

.

2021

;

62

(

8

):

1990

-

1994

.

20.

Huynh

HH

,

Pressiat

C

,

Sauvageon

H

, et al.

Development and validation of a simultaneous quantification method of 14 tyrosine kinase inhibitors in human plasma using LC-MS/MS

.

Ther Drug Monit

.

2017

;

39

(

1

):

43

-

54

.

21.

O’Hare

T

,

Shakespeare

WC

,

Zhu

X

, et al.

AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance

.

Cancer Cell

.

2009

;

16

(

5

):

401

-

412

.

22.

Cortes

JE

,

Kantarjian

H

,

Shah

NP

, et al.

Ponatinib in refractory Philadelphia chromosome–positive leukemias

.

N Engl J Med

.

2012

;

367

(

22

):

2075

-

2088

.

23.

Laramy

JK

,

Kim

M

,

Parrish

KE

,

Sarkaria

JN

,

Elmquist

WF

.

Pharmacokinetic assessment of cooperative efflux of the multitargeted kinase inhibitor ponatinib across the blood-brain barrier

.

J Pharmacol Exp Ther

.

2018

;

365

(

2

):

249

-

261

.

24.

Center for Drug Evaluation and Research

.

CEDR Pharmacology Review: Iclusig

. Accessed 2 January 2024. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203469orig1s000clinpharmr.pdf.

25.

Haddad

FG

,

Jabbour

E

,

Short

NJ

, et al.

Chemotherapy-free combination of blinatumomab and ponatinib in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: updates from a phase II trial [abstract]

.

Blood

.

2023

;

142

(

suppl 1

):

2827

.